Treatment details of lenalidomide (CC-5013) therapy in myelofibrosis with myeloid metaplasia involving 27 patients from Mayo Clinic and 41 patients from MDACC
. | Mayo Clinic . | MDACC . |
|---|---|---|
| Planned treatment schedule | Three cycles for all patients | 3-4 months for all patients |
| Six cycles for treatment responders | 24 months for responders | |
| One cycle of treatment | Lenalidomide 10 mg/day × 28 days | Lenalidomide 10 mg/day × 28 days (5 mg/day if platelet count less than 100 × 109/L) |
| Pertinent eligibility criteria | AMM, PPMM, or PTMM | AMM, PPMM, or PTMM |
| Hemoglobin level no more than 100 g/L | Platelet count at least 30 × 109/L | |
| Neutrophil count at least 1 × 109/L | No hemoglobin or neutrophil requirement | |
| Platelet count at least 100 × 109/L | ||
| No. patients who received | ||
| Less than 1 cycle of treatment | 2 | 2 |
| 1 to less than 3 cycles | 11 | 14 |
| 3 to 6 cycles | 14 | 13 |
| More than 6 cycles | Treatment stopped after 6 cycles | 12 |
| No. patients who required dose modification | 6 (22%) | 10 (24%) |
. | Mayo Clinic . | MDACC . |
|---|---|---|
| Planned treatment schedule | Three cycles for all patients | 3-4 months for all patients |
| Six cycles for treatment responders | 24 months for responders | |
| One cycle of treatment | Lenalidomide 10 mg/day × 28 days | Lenalidomide 10 mg/day × 28 days (5 mg/day if platelet count less than 100 × 109/L) |
| Pertinent eligibility criteria | AMM, PPMM, or PTMM | AMM, PPMM, or PTMM |
| Hemoglobin level no more than 100 g/L | Platelet count at least 30 × 109/L | |
| Neutrophil count at least 1 × 109/L | No hemoglobin or neutrophil requirement | |
| Platelet count at least 100 × 109/L | ||
| No. patients who received | ||
| Less than 1 cycle of treatment | 2 | 2 |
| 1 to less than 3 cycles | 11 | 14 |
| 3 to 6 cycles | 14 | 13 |
| More than 6 cycles | Treatment stopped after 6 cycles | 12 |
| No. patients who required dose modification | 6 (22%) | 10 (24%) |